Tietze C, Lewit S. Evaluation of intrauterine devices: ninth progress report of the Cooperative Statistical Program. Stud Fam Plann 1970;1:1–40.
103.
Lippes J, Zielezny M. The loop decade. Mt Sinai J Med 1975;4:353– 356.
104.
Ronnerdag M, Odlind V. Late bleeding problems with the levonorgestrel-releasing intrauterine system: evaluation of the endometrial cavity. Contraception 2007;75:268–270.
105.
Benaceraf BC, Shipp TD, Bromley B. Three-dimensional ultrasound detection of abnormally located intrauterine contraceptive devices which are a source of pelvic pain and abnormal bleeding. Ultrasound Obstet Gynecol 2009;34:110–115.
106.
Coffee AL, Kuehl TJ, Willis S, et al. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol 2006;195:1311–1319.
107.
Johansson EDB, Sitruk-Ware R. New delivery systems in contraception: vaginal rings. Am J Obstet Gynecol 2004;190:S54–S59.
108.
Spelsberg TC, Rories C, Rejman JJ. Steroid action on gene expression: possible roles of regulatory genes and nuclear acceptor sites. Biol Reprod 1989;40:54–69.
109.
Phillips A. The selectivity of a new progestin. Acta Obstet Gynecol Scand 1990;152(Suppl):21–24.
110.
Oelkers W. Drospirenone, a progestin with antimineralocorticoid properties: a short review. Mol Cell Endocrinol 2004;217:255–261.
111.
Suthipongse W, Taneepanichskul S. An open label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30 microg ethinylestradiol and 150 microg levonorgestrel/30 microg ethinylestradiol in Thai women. Contraception 2004;69;23–26.
112.
Guido M, Romualdi D, Guiliani M, et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 2004;89:2817–2823.
113.
Kelly S, Davies E, Fearns S, et al. Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study. Clin Drug Investig 2010;30:325–326.
114.
Jensen JT. Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest. Expert Opin Pharmacother 2010;11:1147– 1157.
115.